PriceTargets.com logo

Prime Medicine - PRME Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.75
  • Forecasted Upside: 15.80%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$20.51 As of 02/7/2023 01:00 AM ET
▲ +0.22 (1.08%)

This chart shows the closing price for PRME by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Prime Medicine Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for PRME and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for PRME

Analyst Price Target is $23.75
▲ +15.80% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Prime Medicine in the last 3 months. The average price target is $23.75, with a high forecast of $27.00 and a low forecast of $21.00. The average price target represents a 15.80% upside from the last price of $20.51.

This chart shows the closing price for PRME for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 polled investment analysts is to buy stock in Prime Medicine.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
1/24/2023Morgan StanleyLower TargetEqual Weight$23.00 ➝ $21.00
11/14/2022JPMorgan Chase & Co.Initiated CoverageOverweight$27.00
11/14/2022Morgan StanleyInitiated CoverageEqual Weight$23.00
11/14/2022Jefferies Financial GroupInitiated CoverageBuy$25.00
11/14/2022The Goldman Sachs GroupInitiated CoverageNeutral$22.00
(Data available from 2/7/2018 forward)

News Sentiment Rating

1.75 (Strong Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/10/2022
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
12/9/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
1/8/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

Prime Medicine logo
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $20.51
Low: $19.83
High: $21.23

50 Day Range

MA: $17.38
Low: $15.85
High: $21.11

52 Week Range

Now: $20.51
Low: $14.52
High: $21.73

Volume

227,689 shs

Average Volume

155,336 shs

Market Capitalization

$1.93 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Prime Medicine?

The following Wall Street research analysts have issued reports on Prime Medicine in the last twelve months: Jefferies Financial Group Inc., JPMorgan Chase & Co., Morgan Stanley, and The Goldman Sachs Group, Inc..
View the latest analyst ratings for PRME.

What is the current price target for Prime Medicine?

4 Wall Street analysts have set twelve-month price targets for Prime Medicine in the last year. Their average twelve-month price target is $23.75, suggesting a possible upside of 13.3%. JPMorgan Chase & Co. has the highest price target set, predicting PRME will reach $27.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $21.00 for Prime Medicine in the next year.
View the latest price targets for PRME.

What is the current consensus analyst rating for Prime Medicine?

Prime Medicine currently has 2 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe PRME will outperform the market and that investors should add to their positions of Prime Medicine.
View the latest ratings for PRME.

What other companies compete with Prime Medicine?

Other companies that are similar to Prime Medicine include Twist Bioscience, Recursion Pharmaceuticals, ImmunityBio, Arcellx and Replimune Group. Learn More about companies similar to Prime Medicine.